Dr. Robert P. Giugliano is a Senior Investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Staff Physician in the Cardiovascular Division at the Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, Boston, USA. He graduated summa cum laude and phi beta kappa from Dartmouth College, and received his medical degree at Harvard Medical School. Dr Giugliano completed his internship, residency and chief residency at Cedars-Sinai Medical Centre, Los Angeles, USA, and then returned to Boston as a Cardiology Fellow at the Massachusetts General Hospital, USA.
His research interests include novel lipid-lowering therapies, antithrombotic therapies for atrial fibrillation and acute coronary syndromes (ACS), and the assessment of outcomes in patients with ACS. Dr Giugliano has authored more than 350 original articles and 250 reviews/editorials/book chapters. He is the Founding Scientific Advisor and Editor-in-Chief for MD Conference Express, Co-Editor-in-Chief of Cardiology and Therapy, and serves on editorial boards for Circulation, The American Heart Journal, Clinical Cardiology, Cor et Vasa, Hospital Practice, Cardiovascular Therapeutics and Clinical Pathways in Cardiology.
Dr Giugliano is the Principal TIMI Investigator for over a dozen clinical trials including the VESALIUS-CV trial with evolocumab, ENGAGE AF-TIMI 48 trial with edoxaban, and Executive Committee member of several additional trials including the IMPROVE-IT (ezetimibe), FOURIER (evolocumab), AZALEA-TIMI 71 (abelacimab) and CORE trials (olezarsen) trials.
David A. Morrow, MD, MPH is the Director of the Samuel A. Levine Cardiac Intensive Care Unit in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, Section Head of Critical Care Cardiology, and a Professor of Medicine at Harvard Medical School. Dr. Morrow earned his medical degree from Harvard Medical School and a Masters in Public Health with a concentration in clinical study design and interpretation from the Harvard School of Public Health. He completed his medical residency in Internal Medicine and fellowship in Cardiovascular Medicine at Brigham and Women’s Hospital.
Dr. Morrow is a Senior Investigator in the Thrombolysis in Myocardial Infarction Study Group at Brigham and Women’s Hospital with a research focus in the management of unstable and stable coronary artery disease. He also directs the TIMI Biomarker Program.
Dr. Morrow is an internationally recognized expert in risk stratification in patients with ischemic heart disease. He has served on the National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines Committee on Biochemical Cardiac Markers for which he led the clinical section on acute coronary syndromes, and on the Program Committee for the American Heart Association Council on Clinical Cardiology. He is a member of the Global Task Force for a Universal Definition of Myocardial Infarction and of the American College of Cardiology/American Heart Association Guidelines Committee for Management of ST-elevation Myocardial Infarction. He sits on the editorial boards of the American Heart Journal, Circulation, Clinical Chemistry, European Heart Journal: Acute Cardiovascular Care, and the Journal of the American College of Cardiology. He has been a special section Co-Editor for Continuing Medical Education at Circulation. Dr. Morrow has more than 150 original scientific reports, reviews, editorials, book chapters and electronic publications in his areas of expertise, and is the editor of Cardiovascular Biomarkers, a text on application of biomarkers in Cardiovascular disease.
Benjamin Scirica, MD, MPH graduated from Harvard Medical School and trained in internal medicine and cardiovascular medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He has a Master of Public Health degree from Harvard School of Public Health. He is currently Professor of Medicine at Harvard Medical School and Senior Investigator at the TIMI Study Group. He is Director of Innovation in the cardiovascular division at Brigham and Women’s Hospital.
His research interests center on the identification and application of novel cardiac biomarkers and therapeutic strategies across the spectrum of cardiometabolic disease. He was principal investigator of the AVANT GARDE-TIMI 43 trial and CAMELLIA-TIMI 61 and co-investigator of the MERLIN-TIMI 36, TRA 2Pº-TIMI 50, and SAVOR-TIMI 53 trials. He is the Director of the TIMI ECG Core Laboratory, which has analyzed over 20,000 continuous and static ECGs from multiple trials in acute coronary syndromes.
Dr. Scirica has authored or co-authored over 100 peer-reviewed articles, serves on the editorial board of ACCEL, and is a reviewer for multiple journals, including The Lancet, Circulation and Journal of the American College of Cardiology (JACC). He practices in the Levine Cardiac Intensive Care Unit, cardiology in-patient service, and the Watkins Cardiovascular Clinic at Brigham and Women’s Hospital.
Michelle O’Donoghue, MD, MPH holds the inaugural McGillycuddy-Logue Endowed Chair in Cardiology at Brigham and Women’s Hospital. She is an Associate Physician in the Cardiovascular Division of Brigham and Women’s Hospital, an Affiliate Physician in the Cardiovascular Division of Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. She has been working as an investigator with the TIMI Study Group since 2005.
Dr. O’Donoghue’s primary research focus is the design and conduct of multicenter clinical trials for patients with stable and unstable heart disease, in addition to other related disease states. She also has a particular research interest in women’s cardiovascular health. She is currently the global Principal Investigator of the OCEAN(a)-Outcomes trial, the phase 3 trial of lowering lipoprotein(a) with the siRNA olpasiran. She is also the global Principal Investigator of the GOLDILOX-TIMI 69 trial, a phase 2b trial of a novel LOX-1 inhibitor. She is also serving as a National Coordinator for the HPS-4/TIMI 55 ORION-4 trial, the phase III trial of the novel PCSK9 inhibitor inclisiran. She previously led the SOLID-TIMI 52 trial, the phase III trial of the direct Lp-PLA2 inhibitor darapladib in patients after an acute coronary syndrome. She also served as the National Lead Investigator for the LATITUDE-TIMI 60 trial, the phase III randomized trial of losmapimod in ACS patients. Prior trial leadership also includes the PRINCIPLE-TIMI 44 trial (a pharmacodynamic study of prasugrel versus clopidogrel in PCI) and the LANCELOT phase II program of the PAR-1 antagonist atopaxar. She has been the project Principal Investigator for the cardiovascular risk assessment of two investigational therapeutics in the field of bone metabolism. She was the local Principal Investigator of the PEGASUS-TIMI 54 trial and the CAMELLIA-TIMI 61 trial. Additional clinical research interests include the evaluation of novel antiplatelet drugs, established and novel biomarkers, the study of women and heart disease and the development of novel therapeutics in the management of acute coronary syndromes and diabetes mellitus.
Dr. O’Donoghue was born in Toronto and earned her medical degree from Columbia University College of Physicians and Surgeons in New York. She completed her residency in internal medicine and fellowship in cardiovascular medicine at Massachusetts General Hospital. She subsequently completed a Masters in Public Health degree at the Harvard School of Public Health.
Christian T. Ruff, MD, MPH is an Associate Physician in the Cardiovascular Division at Brigham and Women’s Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Ruff graduated from Harvard University, earned his medical degree at Johns Hopkins University School of Medicine, and his masters of public health from the Harvard School of Public Health. Dr. Ruff completed his internal medicine residency and cardiovascular medicine fellowship at the Brigham and Women’s Hospital. Dr. Ruff is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group and serves the Director of the Genetics Core Laboratory and the Co-Chairman of the Clinical Events Committee. He has led a broad array of projects, ranging from investigator initiated studies of biomarkers and genetic variants to large clinical trials. Dr. Ruff has investigated the efficacy of safety of antithrombotic therapies across the spectrum of cardiovascular disease, with a focus on stroke prevention in atrial fibrillation. Dr. Ruff has served on international antithrombotic guideline committees and has been invited to give hundreds of lectures nationally and internationally. He has authored many scholarly articles, editorials, reviews, and book chapters that include the New England Journal of Medicine, Lancet, Journal of the American Medical Association, American Journal of Medicine, Circulation, Journal of the American College of Cardiology, and Nature Reviews Cardiology.